Circulating (plasma/serum) levels of FGF-2 are higher in CLL patients than in healthy controls [2,55,57,65,77,80,85,88,89,96,99,102,109] (Table 1). This evidence concerns the gene FGF2 and B-cell chronic lymphocytic leukemia.